Quốc gia: Hoa Kỳ
Ngôn ngữ: Tiếng Anh
Nguồn: NLM (National Library of Medicine)
RALTEGRAVIR POTASSIUM (UNII: 43Y000U234) (RALTEGRAVIR - UNII:22VKV8053U)
State of Florida DOH Central Pharmacy
RALTEGRAVIR POTASSIUM
RALTEGRAVIR 400 mg
ORAL
PRESCRIPTION DRUG
ISENTRESS1 is indicated in combination with other anti-retroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients. This indication is based on analyses of plasma HIV-1 RNA levels up through 48 weeks in three double-blind controlled studies of ISENTRESS. Two of these studies were conducted in clinically advanced, 3-class antiretroviral (NNRTI, NRTI, PI) treatment-experienced adults and one was conducted in treatment-naïve adults. The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response [see Clinical Studies (14)] . The safety and efficacy of ISENTRESS have not been established in pediatric patients. Registered trademark of MERCK & CO., Inc. COPYRIGHT © 2007, 2009 MERCK & CO., Inc. All rights reserved None Pregnancy Category C ISENTRESS should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. There are no adequate and well-controlled studies in pregnant women. In addi
ISENTRESS tablets 400 mg are pink, oval-shaped, film-coated tablets with “227” on one side. They are supplied by State of Florida DOH Central Pharmacy as follows: Storage and Handling Store at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F). See USP Controlled Room Temperature.
New Drug Application
ISENTRESS - RALTEGRAVIR TABLET, FILM COATED STATE OF FLORIDA DOH CENTRAL PHARMACY ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ISENTRESS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ISENTRESS. ISENTRESS (RALTEGRAVIR) TABLETS INITIAL U.S. APPROVAL: 2007 RECENT MAJOR CHANGES Indications And Usage (1) 07/2009 Dosage And Administration (2) 01/2009 Warnings And Precautions (5.2) - removal 07/2009 INDICATIONS AND USAGE ISENTRESS® is a human immunodeficiency virus integrase strand transfer inhibitor (HIV-1 INSTI) indicated: In combination with other antiretroviral agents for the treatment of HIV-1 infection in adult patients (1). The safety and efficacy of ISENTRESS have not been established in pediatric patients (1). DOSAGE AND ADMINISTRATION 400 mg administered orally, twice daily with or without food (2). During coadministration with rifampin, 800 mg twice daily (2). DOSAGE FORMS AND STRENGTHS TABLETS: 400 mg (3). CONTRAINDICATIONS None (4) WARNINGS AND PRECAUTIONS Monitor for Immune Reconstitution Syndrome (5.1). ADVERSE REACTIONS The most common adverse reactions of moderate to severe intensity (≥2%) which occurred at a higher rate than the comparator are insomnia, headache, nausea, asthenia and fatigue (6.1). Creatine kinase elevations were observed in subjects who received ISENTRESS. Myopathy and rhabdomyolysis have been reported; however, the relationship of ISENTRESS to these events is not known. Use with caution in patients at increased risk of myopathy or rhabdomyolysis, such as patients receiving concomitant medications known to cause these conditions (6.1). TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT MERCK & CO., INC. AT 1-877-888-4231 OR FDA AT 1- 800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH. DRUG INTERACTIONS Coadministration of ISENTRESS with drugs that are strong inducers of UGT1A1 may result in reduced plasma concentrations of raltegravir (7.2). USE IN SPECIFIC POPULATIONS Pre gnancy: ISENTRESS should be used during pre Đọc toàn bộ tài liệu